Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
about
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell linesLung cancer biomarkers, targeted therapies and clinical assaysTheragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitorsStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerMolecular pathology of lung cancer: key to personalized medicine.Mechanisms of drug resistance in kinases.EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutationsTransforming growth factor β signaling overcomes dasatinib resistance in lung cancerHedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinomaEfficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient.Snapback primer mediated clamping PCR for detection of EGFR and KRAS mutations in NSCLC patients by high resolution melting analysisIn silico insight into EGFR treatment in patients with lung carcinoma and T790M mutationsCOLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma.U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma.Nuclear trafficking of the epidermal growth factor receptor family membrane proteins.CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancerTargeted Therapies in Lung Cancer.ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer.FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors.Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers.Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.Mutational analysis and clinical correlation of metastatic colorectal cancer.Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profilesTherapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Trial Watch: Immunostimulatory cytokines.Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor familyCrosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition.
P2860
Q24312998-8C61EE10-8C7A-41EF-8152-A1D44D2B0A0EQ26775396-E579FB03-D7B9-429C-9DE4-ADB48FE9EF61Q26824717-54EFDCD3-112D-4CF9-9CA7-EFA9C81200F7Q27680966-4E26FA0C-E723-418E-AB24-E30EB7A8B459Q27691299-E5B08216-7946-486C-A5E0-4FD6BF4DA8F9Q27692567-D8883320-2E5E-415A-A742-D55898EEB2CCQ27851583-E21C8FB4-5C95-4680-A37B-8F6E9B0E2DDAQ27851592-C4E138B5-8213-4A91-BAE3-7900F92951CEQ27853189-8C0DCF4C-A835-4C69-9F0F-C3AC33555847Q27853391-07C6A31A-D3A2-4D8B-8A3C-45C349059FC3Q28384015-279B1FB4-B936-40E4-9C3E-2A26BBA84372Q28542671-27D6A639-AB5A-4083-B29F-B441843B495AQ28595500-E0E5C1E0-1F33-491F-A3B4-4590BED1EAECQ33418555-3A89A644-DDE0-4101-A906-9A231F950B90Q33563803-0635108D-2041-4151-A53E-58E57A95F511Q33632656-E1B3130C-3E2F-41AC-9AC1-747FECA26287Q33634383-F2DF9AF1-0526-4A45-A779-DD63D2A6D3D9Q33724006-E397B882-F264-4575-BCA1-BF989399BF7CQ33756779-0635BE7E-B79B-4691-B639-91D13C8467B6Q33829794-151B1C0A-413A-4DDC-9764-1647335A6AD8Q33947130-BEB23C68-0633-4EA2-A014-938D744F24C8Q33998459-C6F30ADD-CA55-4056-871A-69D4BA2B45AEQ34023291-6065BCB6-FAAA-4CE6-94AF-07A87FEBED1EQ34030379-9DC9C2D2-0DF9-4630-B8F4-6BB66D688A5DQ34162084-A08B6091-69D9-4412-9A18-16682924A8CBQ34359341-34C153D5-A4A5-4822-A042-B17FFCFC7EF9Q34497010-C1B60B8D-0CAF-4E2B-8872-EF96CB6E3AE9Q34705006-56AAB0DE-9332-4849-8365-431A7B7532DAQ34790125-4437582E-98CF-412A-AA50-037C4A12D81DQ34979243-6FC90D8B-C3AC-49D8-8B12-A1633EC00EE4Q35082873-C782D2F5-67D8-4154-B7A2-D71E5347A1CDQ35220347-D0631993-827E-4A40-B6B3-B6081E0AB1D9Q35450437-CFC5ADAC-D48F-4690-B573-0C449BB85F49Q35558988-B6FD1127-F833-4FEC-A3F5-82E150369B3BQ35884591-92575A15-E0D1-4537-9E2C-719FF089EC2CQ35889673-57EDE501-3ED3-4A88-A68C-7688A591AA43Q35986801-22F923E4-BD21-4DA3-94BE-22CC222CE558Q36057492-6E30F550-1606-426D-83F7-DE58EAE03A5CQ36162605-8E379949-6C42-4F25-A603-3D95383571A6Q36365503-A867B631-0CDD-4F87-B66D-4B9D6948A888
P2860
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
@en
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
@nl
type
label
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
@en
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
@nl
prefLabel
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
@en
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
@nl
P2093
P1476
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
@en
P2093
Dimitrios Bafaloukos
Helena Linardou
Issa J Dahabreh
Paris Kosmidis
Samuel Murray
P2860
P2888
P304
P356
10.1038/NRCLINONC.2009.62
P407
P577
2009-06-01T00:00:00Z
P6179
1009425028